In a preclinical orthotopic model of RCC, for example, it has been demonstrated that the administration of pharmacological inhibitors that target the transforming growth factor-beta (TGF-β) pathway efficiently restores the expression levels of TCA cycle enzymes 60. Here, TGFB1 is linked to renal cell carcinoma.